INS and type 2 diabetes mellitus: In conclusion, 1500 mg bid imeglimin treatment for 18 weeks significantly improves glucose tolerance; this is due to a substantial beneficial effect on insulin secretion in response to glucose and is also potentially contributed to by an impact on insulin sensitivity in T2D patients.